265 related articles for article (PubMed ID: 25724156)
1. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
de Jong J; Sukbuntherng J; Skee D; Murphy J; O'Brien S; Byrd JC; James D; Hellemans P; Loury DJ; Jiao J; Chauhan V; Mannaert E
Cancer Chemother Pharmacol; 2015 May; 75(5):907-16. PubMed ID: 25724156
[TBL] [Abstract][Full Text] [Related]
2. Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
de Vries R; Smit JW; Hellemans P; Jiao J; Murphy J; Skee D; Snoeys J; Sukbuntherng J; Vliegen M; de Zwart L; Mannaert E; de Jong J
Br J Clin Pharmacol; 2016 Feb; 81(2):235-45. PubMed ID: 26382728
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Marostica E; Sukbuntherng J; Loury D; de Jong J; de Trixhe XW; Vermeulen A; De Nicolao G; O'Brien S; Byrd JC; Advani R; McGreivy J; Poggesi I
Cancer Chemother Pharmacol; 2015 Jan; 75(1):111-21. PubMed ID: 25381051
[TBL] [Abstract][Full Text] [Related]
4. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
5. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies.
Williams DD; Peng B; Bailey CK; Wire MB; Deng Y; Park JW; Collins DA; Kapsi SG; Jenkins JM
Clin Ther; 2009 Apr; 31(4):764-76. PubMed ID: 19446149
[TBL] [Abstract][Full Text] [Related]
6. Impact of food and different meal types on the pharmacokinetics of rilpivirine.
Crauwels HM; van Heeswijk RP; Buelens A; Stevens M; Boven K; Hoetelmans RM
J Clin Pharmacol; 2013 Aug; 53(8):834-40. PubMed ID: 23720136
[TBL] [Abstract][Full Text] [Related]
7. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
8. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
9. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
10. The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure.
de Jong J; Haddish-Berhane N; Hellemans P; Jiao J; Sukbuntherng J; Ouellet D
Cancer Chemother Pharmacol; 2018 Aug; 82(2):299-308. PubMed ID: 29882017
[TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS.
Wire MB; Bruce J; Gauvin J; Pendry CJ; McGuire S; Qian Y; Brainsky A
Clin Ther; 2012 Mar; 34(3):699-709. PubMed ID: 22336488
[TBL] [Abstract][Full Text] [Related]
12. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
13. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
14. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Michallet AS; Dilhuydy MS; Subtil F; Rouille V; Mahe B; Laribi K; Villemagne B; Salles G; Tournilhac O; Delmer A; Portois C; Pegourie B; Leblond V; Tomowiak C; de Guibert S; Orsini F; Banos A; Carassou P; Cartron G; Fornecker LM; Ysebaert L; Dartigeas C; Truchan Graczyk M; Vilque JP; Aurran T; Cymbalista F; Lepretre S; Lévy V; Nguyen-Khac F; Le Garff-Tavernier M; Aanei C; Ticchioni M; Letestu R; Feugier P
Lancet Haematol; 2019 Sep; 6(9):e470-e479. PubMed ID: 31324600
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics of ibrutinib in subjects with varying degrees of hepatic impairment.
de Jong J; Skee D; Hellemans P; Jiao J; de Vries R; Swerts D; Lawitz E; Marbury T; Smith W; Sukbuntherng J; Mannaert E
Leuk Lymphoma; 2017 Jan; 58(1):185-194. PubMed ID: 27267254
[TBL] [Abstract][Full Text] [Related]
16. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
[TBL] [Abstract][Full Text] [Related]
17. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
18. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the effects of a high-fat meal on the oral bioavailability of a single dose of preladenant in healthy subjects.
Cutler DL; Tendolkar A; Grachev ID
J Clin Pharmacol; 2012 Nov; 52(11):1698-703. PubMed ID: 22167566
[TBL] [Abstract][Full Text] [Related]
20. Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants.
Shimizu H; Nishimura Y; Shiide Y; Akimoto M; Matsuda H; Kato Y; Hirai M
Clin Ther; 2022 Dec; 44(12):1552-1565. PubMed ID: 36376130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]